A tedizolid-resistant isolate of MRSA was selected by serial passage. Whole genome 25 sequencing revealed only a single nucleotide variant in rpoB. Cross-resistance to linezolid, 26 109
chloramphenicol, and quinupristin-dalfopristin was observed but susceptibility to other drugs 27 including rifampin was unchanged. Models of the RNA-polymerase-ribosomal complex revealed 28 that the mutated residue was unlikely to interact directly with the oxazolidinone binding site. This 29 is the first time that rpoB mutation has been associated with resistance to the PhLOPSa 30 antimicrobials. 31
Tedizolid is an oxazolidinone antimicrobial with broad spectrum activity against positive bacteria including methicillin-resistant S. aureus (MRSA). 1 Like other oxazolidinones 33 tedizolid exerts its antibacterial activity by binding the 23s rRNA component of the 50s-34 ribosomal subunit and thus inhibiting protein synthesis. Resistance to tedizolid is uncommon but 35 mutations in the ribosomal proteins L3, L4, and L22 (encoded by rplC, rplD, and rplV 36 respectively), and the 23S rRNA target, which also mediate the so-called PhLOPSa (phenicol, 37 lincosamide, oxazolidinone, pleuromutilin, and streptogramin A) resistance phenotype have 38 been implicated. 2, 3 Acquisition of the transferable rRNA methyltransferase gene, cfr, may also 39 cause resistance to linezolid and other PhLOPSa antimicrobials but is generally believed to be 40 insufficient to produce tedizolid resistance on its own even though it may increase the tedizolid 41 MIC. The plasmid-carried optrA gene, which encodes an ABC transporter, has been implicated 42 in oxazolidinone and phenicol resistance in enterococci and streptococci but has not been 43 identified in S. aureus. 4 Previous serial passage studies with tedizolid have seen limited success 44 in selecting for tedizolid resistance and only mutations in the 23S rRNA have been recovered 45 following tedizolid exposure. 5 Genes affecting quinolone efflux such as norA and mepA, or 46 lincosamide efflux such as mdeA have not been reported to affect oxazolidinone activity. 47
In this study, we observed the emergence of a mutant exhibiting a novel mechanism of 48 PhLOPSa resistance from a well characterized MRSA strain after serial passage in escalating 49 concentrations of tedizolid. 50
Using the well characterized MRSA strain, N315, we selected for tedizolid resistance by 51 serial passage in escalating concentrations of tedizolid in Mueller Hinton II broth (MHB) starting 52 with 0.5x the MIC. Once visible growth was observed a sample of the broth was diluted 1:1000 53 into fresh MHB with twice the previous concentration of tedizolid until an isolate with an MIC of 54 ≥4 mg/mL was recovered. This MIC was selected since it is 1 log 2 dilution above the breakpoint 55 for resistance (MIC ≥ 2mg/L). After 10 passages, we recovered an isolate (N315-TDZ4) with a 56 stable tedizolid MIC of 4mg/L or 16x the MIC of the parent strain, N315. To explore the cross 57 resistance associated with this evolved strain we reevaluated susceptibility to a panel of other 58 antimicrobial agents (Table 1) 
by broth microdilution in accordance with Clinical Laboratory 59
Standards Institute (CLSI) guidelines 6 or by gradient strip in the case of quinupristin-dalfopristin 60 (Liofilchem®). Cross-resistance to chloramphenicol, linezolid, and quinupristin-dalfopristin was 61 observed but susceptibility to other drugs tested was relatively unchanged (Table 1) . N315 is 62 resistant to clindamycin so lincosamide cross-resistance was unevaluable in this study and we 63 did not have access to pleuromutilins, which are not yet a clinically important class of 64 antimicrobials. While macrolide susceptibility is not considered part of the PhLOPSa group 65 macrolides also target the 50s ribosome, however, erythromycin susceptibility was also 66 unevaluable since N315 is resistant to erythromycin at baseline. 67 N315-TDZ4 was subjected to whole genome sequencing (WGS) using the MiSeq 68 platform (Illumina, San Diego, CA, USA) as previously described 7 to an average read depth of at 69 least 50X per isolate and the. Sequence data from this study is freely available through the 70 NCBI Sequence Read Archive (PRJNA578164). WGS of the N315-TDZ4 and comparison to the 71 parent strain revealed a single nucleotide variant (SNV) in the rpoB gene (1345 A>G) 72 corresponding to the amino acid substitution Asn449Asp. This mutation lies outside of the 73 rifampin resistance-determining regions, which span from nucleotides 1384 -1464 (AA 462-74 488) and 1543 -1590 (AA 462-488) 8, 9 , and we correspondingly did not observe any change in 75 rifampin susceptibly (Table 1 ). Previous studies have reported an association between 76 vancomycin and daptomycin susceptibility and certain rpoB mutations including Ala621Glu, and 77 Ala477Asp, and His481Tyr. [10] [11] [12] We did not observe any change in daptomycin MIC for our 78 mutant but we did see a 1 log 2 -dilution increase in vancomycin MIC. To further assess the 79 potential significance of this increase in vancomycin MIC we tested the N315-TDZ4 isolate and 80 N315 parent strains for the heterogeneous vancomycin intermediate S. aureus (hVISA) 81 phenotype by the gold standard population analysis profile (PAP) as previously described. 13 82 Interestingly, we observed that PAP-AUC ratio with Mu3 of N315-TDZ4 was 0.85, up from 0.44 83 of the parent strain N315 (Table 1) . While this increase is substantial it falls below the 84 categorical criterion to declare this isolate an hVISA (PAP AUC ratio with Mu3 of ≥0.9). 85
In an effort to evaluate the potential impact of the rpoB Asn449Asp mutation on target 86 protein function, we constructed a homology model of S. aureus rpoB using I-TASSER, 14 and 87 modeled the relative orientations of the RNA polymerase (RNAP) and the ribosome (Figure 1) . 88
This model suggests that the RNAP mutation would be unlikely to interact directly with binding 89 sites for the oxazolidinones and other PhLOPSa drugs located in the 50S ribosomal subunit 90 ( Figure 1) . This finding suggests an indirect mechanism of resistance, possibly involving one of 91 the many factors that interact with the beta-subunit of RNAP. 8 92
In this study, we report for the first time a novel mechanism of resistance to 93 oxazolidinones, phenicols, and streptogramins involving mutation in rpoB, which encodes the β-94 subunit of RNAP. The precise molecular mechanism by which this mutation mediates this 95 resistance phenotype is unclear but may involve transcriptional modulation by altered sigma-96 factor binding. Previous studies have demonstrated that the 30s-ribosomal protein S10 encoded 97 by rpsJ links directly with the β-subunit of RNAP facilitating the tight linkage between 98 transcription and translation in bacteria but the RNAP only interacts with the leading 30s-subunit 99 and no known interaction between the 50s subunits and the RNAP exist. The fact that cross 100 resistance was isolated to 50s-ribosomally active agents and not 30s active agents 101 (doxycycline) suggests a relatively specific interaction with the 50s-ribosome and not a broader 102 modulation of translation or protein synthesis. Based on the absence of altered susceptibility to 103 other intracellularly active agents including moxifloxacin and doxycycline it seems unlikely that 104 this variant facilitates multidrug efflux. For now, tedizolid resistance remains uncommon 105 clinically and it is unknown whether this unique mutation could be selected for by other 106
PhLOPSa drugs or would be likely to emerge after clinical exposure to tedizolid. 107 108 parentheses. The great distance between the mutated residue and linezolid binding site 185 suggests an indirect mechanism; notably, the susceptibility of doxycycline, which acts 186 on the 30S ribosomal subunit, was not affected. One CryoEM study of the structure of the 187 RNAP-ribosomal complex indicates an S1 protein crosslink between the 30S and RNAP 188 at the helix-turn-helix affected by this mutation. 189
